Midodrine
Cirrhosis
Institute of Liver and Biliary Sciences, IndiaSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 73/ 100
Competitive context
142 Active assets in the Cirrhosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PARITAPREVIR AbbVie | Phase 3 | A |
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE) General Hospital of Shenyang Military Region | Phase 4 | BBB |
Tolvaptan Institute of Liver and Biliary Sciences, India | Phase 4 | BBB |
CHOLYL-LYSL-FLUORESCEIN Norgine | Phase 3 | BBB |
Ribavirin Peking University People's Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Midodrine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →